Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTIS and Haploidentical HCT for Severe Hemoglobinopathies
NCT04776850Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Peptides, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of leuprolide in sickle cell disease (SCD) and beta thalassemia major, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Event-Free Survival at 2 years. Planned start Dec 2020; status: withdrawn.
02
Drugs
leuprolide
03
Conditions
sickle cell disease (SCD)beta thalassemia major
Beyond the preview
Go deeper on NCT04776850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04776850.